Fulcrum Therapeutics price target raised to $25 from $20 at Stifel

Stifel raised the firm’s price target on Fulcrum Therapeutics (FULC) to $25 from $20 and keeps a Buy rating on the shares following what the firm says were “very strong” initial 20 mg pociredir data presented at the ASH medical meeting. These data essentially met the full cohort “bar” at just 6-weeks and efficacy should build meaningfully out to 12-weeks in the full cohort, the analyst tells investors. The firm believes pociredir has now firmly established a favorable risk/benefit profile and expects Fulcrum to expand back to an “all-comers” population over time, the analyst added.